Jaume Pons
Known title: President & CEOCIK: 0001816977
Associated companies
Transaction History
| ALXO | ▼ Sell | Open Market | 1,326 | $2K | 2/19/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 10,796 | $17K | 12/30/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,937 | $5K | 8/14/2024 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 20,000 | $20K | 7/11/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 20,000 | $158K | 7/11/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 10,758 | $63K | 7/1/2024 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 20,000 | $20K | 6/4/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 20,000 | $169K | 6/4/2024 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 20,000 | $20K | 5/6/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 20,000 | $318K | 5/6/2024 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 25,846 | $26K | 4/16/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 50,000 | $710K | 4/16/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 20,000 | $223K | 4/4/2024 | View on chart |
| ALXO | ▲ Buy | Grant | 30,000 | $0 | 2/14/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 7,179 | $108K | 12/29/2023 | View on chart |
| ALXO | ▲ Buy | Grant | 89,000 | $0 | 7/25/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 3,208 | $24K | 6/30/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 3,232 | $36K | 12/29/2022 | View on chart |
| ALXO | ▲ Buy | Grant | 74,000 | $0 | 8/5/2022 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 11,900 | $12K | 2/3/2022 | View on chart |
| ALXO | ▲ Buy | Option Exercise | 12,254 | $23K | 2/3/2022 | View on chart |
| ALXO | ▼ Sell | Open Market | 14,471 | $784K | 10/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,229 | $123K | 10/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 14,471 | $784K | 10/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,229 | $123K | 10/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 4,429 | $327K | 9/20/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 10,322 | $768K | 9/20/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,714 | $129K | 9/20/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 235 | $18K | 9/20/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 7,633 | $456K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 4,007 | $244K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,324 | $82K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,190 | $75K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 556 | $36K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,373 | $90K | 8/19/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 617 | $41K | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.